Earlier Identification and Treatment of Keratoconus Progression: Managing the Complex Cornea Patient

Earlier Identification and Treatment of Keratoconus Progression Managing the Complex Cornea Patient
Details
Download PDF
  • Overview

    Content Source

    This continuing medical education (CME) activity captures content from a live satellite symposium.

    Activity Description

    This supplement summarizes presentations by an expert panel that focused on earlier identification and treatment of keratoconus progression and best practices in managing complex corneas in their patient populations.

    Target Audience

    This certified CME activity is designed for ophthalmologists.

    This activity is supported by unrestricted educational grants from AcuFocus, Avellino, and Glaukos.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Review the prevalence of keratoconus and the prevalence of complex corneas among refractive surgery and cataract surgery candidates
    • Improve understanding of new technologies for the identification of inherited risk factors before or early in the progression of corneal disease
    • Understand how cross-linking technology can help halt the progression of keratoconus
    • Identify techniques and technologies to improve visual quality and patient satisfaction in complex cornea patients presenting for cataract and refractive surgery
    • Accreditation

      This educational activity is provided by Evolve Medical Education LLC (Evolve).

       

      Accreditation Statement
      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Gerd U. Auffarth, MD, PhD, FEBO

      Gerd U. Auffarth, MD, PhD, FEBO

      Chairman, Department of Ophthalmology, Heidelberg University Eye Hospital
      Director (Head), International Vision Correction Research Centre
      Director (Head), David J. Apple Center for Ocular Pathology
      University-Eye Clinic
      Heidelberg, Germany


      Brandon D. Ayres, MD

      Brandon D. Ayres, MD

      Cornea Service
      Wills Eye Hospital
      Philadelphia, PA


      Nicole Fram, MD

      Nicole Fram, MD

      Managing Partner, Advanced Vision Care
      Clinical Instructor of Ophthalmology
      Stein Eye Institute, UCLA
      Los Angeles, CA


      Elizabeth Yeu, MD

      Elizabeth Yeu, MD

      Virginia Eye Consultants
      Medical Director, CVP Mid-Atlantic
      Cornea, Cataract, External Disease, and Refractive Surgery
      Assistant Professor
      Department of Ophthalmology
      Eastern Virginia Medical School
      Norfolk, VA


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Gerd U. Auffarth, MD, PhD, FEBO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Johnson & Johnson Vision, Oculus, and SIFI. Speaker’s Bureau: AcuFocus, Alcon, Johnson & Johnson Vision, Oculus, and SIFI. Grant/Research: Alcon and SIFI.

      Brandon D. Ayres, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Dompé, Eyevance, Eyepoint Pharmaceuticals, Glaukos, Gore Surgical, Kala, Omeros, Microsurgical Technology, Mojo, Novartis, Sight Sciences, and TearLab. Speaker’s Bureau: Alcon Vision, Allergan, and Dompé.

      Nicole Fram, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Carl Zeiss Meditec, CorneaGen, Johnson & Johnson Vision, Ocular Therapeutix, Orasis Pharmaceuticals, and Oyster Point. Speaker's Bureau: Alcon, Beaver-Visitec, CorneaGen, and Glaukos. Stock/Shareholder: CorneaGen, Ocular Science, and Orasis Pharmaceuticals. Research/Grants: Carl Zeiss Meditec and Ocular Therapeutix.

      Elizabeth Yeu, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Advanced Vision Group, Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, BVI, BlephEx, Bruder, Carl Zeiss Meditec, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Glaukos, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LayerBio, Lensar, Melt, Merck, Mynosys, Novartis, Ocular Science, Ocusoft, Omeros, Oyster Point Pharmaceuticals, Science Based Health, Sight Sciences, Sun Pharmaceutical Industries, Surface, Tarsus, TearLab, Thea, TopCon, and Visus. Research/Grants: Alcon, BioTissue, Johnson & Johnson Vision, Tarsus, TopCon, and TearLab. Stock/Shareholder: Advanced Vision Group, Avellino, BlephEx, CorneaGen, Expert Opinion, LayerBio, Mati, Melt, Modernizing Medicine, Ocular Science, Orasis, Oyster Point Pharmaceuticals, Staar, Tarsus, and Visus.

      The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies. Steve Lenier, writer, had a financial relationship or affiliation with the following ineligible companies in the form of Share/Stockholder:Aura Biosciences, Cidara Therapeutics, Clearside Biomedical, Eyenovia, and Outlook Therapeutics.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Cataract & Refractive Surgery Today, AcuFocus, Avellino, or Glaukos.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Expiration Date:

    1.00 credits
    Completing the pre-test is required to access this content.
    Completing the pre-survey is required to view this content.

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free